Stent Thrombosis

Also known as: Stent thrombosis / Stent thrombois / Vascular stent thrombosis

DrugDrug NameDrug Description
DB06441CangrelorCangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
DB08816TicagrelorTicagrelor, marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU, is a platelet aggregation inhibitor. It is not a prodrug like clopidogrel. The drug was approved for use in the European Union on 3 December 2010 and was given FDA approval on 20 July 2011.
DB00208TiclopidineTiclopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
DrugDrug NamePhaseStatusCount
DB00758Clopidogrel2Completed1
DB00758Clopidogrel3Recruiting1
DB08816Ticagrelor3Recruiting1
DB00945Acetylsalicylic acid4Completed1
DB00758Clopidogrel4Completed1